<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>58(10)</volume><submitter>Carrington EM</submitter><pubmed_abstract>OBJECTIVE: Bcl-xL is an antiapoptotic member of the Bcl-2 family of proteins and a potent regulator of cell death. We investigated the importance of Bcl-xL for beta-cells by deleting the Bcl-x gene specifically in beta-cells and analyzing their survival in vivo and in culture. RESEARCH DESIGN AND METHODS: Islets with beta-cells lacking the Bcl-x gene were assessed in vivo by histology and by treatment of mice with low-dose streptozotocin (STZ). Islets were isolated by collagenase digestion and treated in culture with the apoptosis inducers staurosporine, thapsigargin, gamma-irradiation, proinflammatory cytokines, or Fas ligand. Cell death was assessed by flow cytometric analysis of subgenomic DNA. RESULTS: Bcl-xL-deficient beta-cells developed but were abnormally sensitive to apoptosis induced in vivo by low-dose STZ. Although a small proportion of beta-cells still expressed Bcl-xL, these did not have a survival advantage over their Bcl-xL-deficient neighbors. Islets appeared normal after collagenase isolation and whole-islet culture. They were, however, abnormally sensitive in culture to a number of different apoptotic stimuli including cytotoxic drugs, proinflammatory cytokines, and Fas ligand. CONCLUSIONS: Bcl-xL expression in beta-cells is dispensible during islet development in the mouse. Bcl-xL is, however, an important regulator of beta-cell death under conditions of synchronous stress. Bcl-xL expression at physiological levels may partially protect beta-cells from apoptotic stimuli, including apoptosis because of mediators implicated in type 1 diabetes and death or degeneration of transplanted islets.</pubmed_abstract><journal>Diabetes</journal><pagination>2316-23</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2750233</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Islet beta-cells deficient in Bcl-xL develop but are abnormally sensitive to apoptotic stimuli.</pubmed_title><pmcid>PMC2750233</pmcid><pubmed_authors>Allison J</pubmed_authors><pubmed_authors>Carrington EM</pubmed_authors><pubmed_authors>Jansen E</pubmed_authors><pubmed_authors>Scott CL</pubmed_authors><pubmed_authors>Kos C</pubmed_authors><pubmed_authors>Myers M</pubmed_authors><pubmed_authors>Fynch S</pubmed_authors><pubmed_authors>McKenzie MD</pubmed_authors><pubmed_authors>Kay TW</pubmed_authors><pubmed_authors>Strasser A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Islet beta-cells deficient in Bcl-xL develop but are abnormally sensitive to apoptotic stimuli.</name><description>OBJECTIVE: Bcl-xL is an antiapoptotic member of the Bcl-2 family of proteins and a potent regulator of cell death. We investigated the importance of Bcl-xL for beta-cells by deleting the Bcl-x gene specifically in beta-cells and analyzing their survival in vivo and in culture. RESEARCH DESIGN AND METHODS: Islets with beta-cells lacking the Bcl-x gene were assessed in vivo by histology and by treatment of mice with low-dose streptozotocin (STZ). Islets were isolated by collagenase digestion and treated in culture with the apoptosis inducers staurosporine, thapsigargin, gamma-irradiation, proinflammatory cytokines, or Fas ligand. Cell death was assessed by flow cytometric analysis of subgenomic DNA. RESULTS: Bcl-xL-deficient beta-cells developed but were abnormally sensitive to apoptosis induced in vivo by low-dose STZ. Although a small proportion of beta-cells still expressed Bcl-xL, these did not have a survival advantage over their Bcl-xL-deficient neighbors. Islets appeared normal after collagenase isolation and whole-islet culture. They were, however, abnormally sensitive in culture to a number of different apoptotic stimuli including cytotoxic drugs, proinflammatory cytokines, and Fas ligand. CONCLUSIONS: Bcl-xL expression in beta-cells is dispensible during islet development in the mouse. Bcl-xL is, however, an important regulator of beta-cell death under conditions of synchronous stress. Bcl-xL expression at physiological levels may partially protect beta-cells from apoptotic stimuli, including apoptosis because of mediators implicated in type 1 diabetes and death or degeneration of transplanted islets.</description><dates><release>2009-01-01T00:00:00Z</release><publication>2009 Oct</publication><modification>2021-02-19T23:44:44Z</modification><creation>2019-06-06T21:38:11Z</creation></dates><accession>S-EPMC2750233</accession><cross_references><pubmed>19581414</pubmed><doi>10.2337/db08-1602</doi></cross_references></HashMap>